Turkmenistan has become the first country in Central Asia to register Sputnik V vaccine
Turkmenistan has become the first country in Central Asia to register
Sputnik V vaccine
Moscow, January 18, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the registration of the Russian Sputnik V vaccine against coronavirus by the Ministry of Health and Medical Industry of Turkmenistan.
The vaccine was approved under the emergency use authorization procedure without additional clinical trials in Turkmenistan.
Sputnik V had been registered earlier under the emergency use procedure in Algeria, Argentina, Bolivia, Serbia, Palestine, Venezuela and Paraguay.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
“Turkmenistan became the first country in Central Asia to officially approve the use of the Sputnik V vaccine. Our partners highly appreciated the safety and efficacy of the vaccine, which is one of the world's leading vaccines against coronavirus and has already been approved by regulators in various regions of the world. Vaccination of the population with the proven Sputnik V vaccine created on a well-researched human adenoviral vectors platform is one of the key elements in preventing the spread of coronavirus”.
Sputnik V has a number of key advantages:
· Efficacy of Sputnik V is over 90%, with full protection against severe cases of COVID-19.
· The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
· Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
· The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
· Over 1.5mn people have already been vaccinated with Sputnik V.
· The developers of the Sputnik V vaccine are working collaboratively with AstraZeneca on a joint clinical trial to improve the efficacy of AstraZeneca vaccine.
· The Sputnik V vaccine has been approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela and Paraguay; the process to approve the vaccine in the EU has been initiated.
· There are no strong allergies caused by Sputnik V.
· The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.
· The price of Sputnik V is less than $10 per shot, making it affordable around the world.